Nutra Pharma Corp (NPHC) Notes Payables (2012 - 2026)

Nutra Pharma has disclosed Notes Payables across 14 years of filings, most recently posting $2.0 million for Q2 2026.

• In Q2 2026, Notes Payables rose 120.35% year-over-year to $2.0 million; the TTM figure through Jun 2026 stood at $2.0 million (up 120.35% YoY), while the FY2025 annual figure was $960382.0, up 35.63% from the prior year.
• Notes Payables came in at $2.0 million for Q2 2026 at Nutra Pharma, up from $983952.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $6.1 million in Q1 2022 to a low of $629579.0 in Q4 2022.
• Average Notes Payables over 5 years is $1.7 million, with a median of $816315.5 recorded in 2024.
• Year-over-year, Notes Payables tumbled 94.03% in 2022 and surged 144.14% in 2025.
• Over 5 years, Notes Payables stood at $629579.0 in 2022, then increased by 5.03% to $661257.0 in 2023, then advanced by 7.09% to $708115.0 in 2024, then soared by 35.63% to $960382.0 in 2025, then jumped by 112.12% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Notes Payables figures were $2.0 million in Q2 2026, $983952.0 in Q1 2026, and $960382.0 in Q4 2025.